Genmab Jumps 8% on Positive Phase 3 Blood Cancer Data

Genmab shares surged 8% on the Copenhagen exchange after reporting successful Phase 3 trial results for a blood cancer treatment. The data likely supports regulatory filings and commercial prospects, though full efficacy and safety details remain undisclosed. This is a company-specific catalyst with limited macro impact.